Drug intelligence / Profile preview

Anti-GD2-CAR engineered T cells

Development stage: Phase 1
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

Anti-GD2-CAR engineered T cells are a type of chimeric antigen receptor (CAR) T-cell therapy designed to target the GD2 ganglioside, a tumor antigen found on various solid tumors, including neuroblastoma, osteosarcoma, and some other sarcomas. The specific construct mentioned is a 3rd generation anti-GD2-CAR (GD2-CAR.OX40.28.z.ICD9) which incorporates a suicide switch (ICD9) that can be activated by the small molecule AP1903 to induce cell death in case of untoward toxicity. This therapy involves engineering a patient's own T cells to express the anti-GD2 CAR, which then enables them to recognize and kill GD2-positive cancer cells.

Other names: anti-GD2-CAR cellsanti-GD-2-CAR cellsanti-GD 2-CAR cells

Targets

GD2

Beyond the preview

Go deeper on Anti-GD2-CAR engineered T cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anti-GD2-CAR engineered T cells.

Explore the full profile